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Abstract
Background: The reporting of outcomes in clinical trials of subjective tinnitus indicates that many different
tinnitus-related complaints are of interest to investigators, from perceptual attributes of the sound (e.g. loudness)
to psychosocial impacts (e.g. quality of life). Even when considering one type of intervention strategy for
subjective tinnitus, there is no agreement about what is critically important for deciding whether a treatment is
effective. The main purpose of this observational study is, therefore to, develop Core Outcome Domain Sets for
the three different intervention strategies (sound, psychological, and pharmacological) for adults with chronic
subjective tinnitus that should be measured and reported in every clinical trial of these interventions. Secondary
objectives are to identify the strengths and limitations of our study design for recruiting and reducing attrition of
participants, and to explore uptake of the core outcomes.
Methods: The ‘Core Outcome Measures in Tinnitus: International Delphi’ (COMIT’ID) study will use a mixed-methods
approach that incorporates input from health care users at the pre-Delphi stage, a modified three-round Delphi survey
and final consensus meetings (one for each intervention). The meetings will generate recommendations by stakeholder
representatives on agreed Core Outcome Domain Sets specific to each intervention. A subsequent step will establish a
common cross-cutting Core Outcome Domain Set by identifying the common outcome domains included in all three
intervention-specific Core Outcome Domain Sets. To address the secondary objectives, we will gather feedback from
participants about their experience of taking part in the Delphi process. We aspire to conduct an observational cohort
study to evaluate uptake of the core outcomes in published studies at 7 years following Core Outcome Set publication.
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Discussion: The COMIT’ID study aims to develop a Core Outcome Domain Set that is agreed as critically important for
deciding whether a treatment for subjective tinnitus is effective. Such a recommendation would help to standardise
future clinical trials worldwide and so we will determine if participation increases use of the Core Outcome Set in the
long term.
Trial registration: This project has been registered (November 2014) in the database of the Core Outcome Measures
in Effectiveness Trials (COMET) initiative.
Keywords: Consensus methods, Core outcome set, Delphi process, Drugs
Background
Tinnitus is the sensation of noise such as ringing, buzz-
ing or hissing sound perceived in the ears or head. Over
70 million people in Europe and more than 50 million
people in the USA experience the condition. In few
cases, tinnitus is objective with vascular or muscular
causes. Most tinnitus cases are subjective, which means
that the sounds are perceived only by the patient, has no
clinically identifiable source of the sound and whose
pathophysiology is not fully understood. This project is
limited to subjective tinnitus, and so in the remainder of
the article wherever we use the term ‘tinnitus’ we are re-
ferring to subjective tinnitus.
Tinnitus is a symptom that can be chronic and disab-
ling for some. However, it is a complex condition that is
challenging to manage because it is associated with a di-
verse range of patient complaints, including perceived
loudness, sleep problems, difficulties in listening and
concentration, effects on psychological wellbeing, daily life
and on general health [1–3]. It may also have negative ef-
fects on personal quality of life, as well as a societal impact
in terms of social withdrawal and impaired work perform-
ance [4, 5]. Each of these patient complaints could be
defined as a domain (i.e. a distinct element) of tinnitus
which could determine how to measure whether a treat-
ment has worked. The process of measuring tinnitus is
made all the more challenging since individual patients
tend to report different profiles of tinnitus-related com-
plaint domains. Moreover, because treatment options re-
main palliative rather than curative any judgements about
therapeutic benefit typically concern a relative improve-
ment and not simply a binary ‘yes/no’ or ‘present/absent’
decision.
At present, there is no consensus on what are the critic-
ally important domains of tinnitus that should be assessed
to determine whether the responses to treatment are bene-
ficial or not for patients. Our recent systematic review
examining 228 published clinical trials for tinnitus, identi-
fied 35 primary domain outcomes and 60 secondary do-
mains’ outcomes spanning nine broad categories (tinnitus
percept, impact of tinnitus, co-occurring complaints,
health-related quality of life, body structures and function,
adverse events or harms, treatment satisfaction, treatment-
related outcomes and ‘unclear or not specified’) [6]. Incon-
sistent outcome reporting can severely hinder identifying
and interpreting the relative merits of the various interven-
tions or therapeutic approaches that are currently on offer
or under investigation [7, 8]. If all clinical trials for tinnitus
used and reported results for the same set of agreed out-
comes, they could be compared and combined. This would
make it much easier to make sense of all the knowledge
produced and reduce unnecessary research waste. The
main goal, therefore, is to advance the standards for clinical
trials of interventions for tinnitus by developing an agreed
list of outcome domains that are critically important for
determining whether a treatment has worked.
Our systematic review of 228 published clinical trials
also identified at least eight broad classes of intervention
strategies that have been assessed in clinical trials [6].
Each of these intervention strategies has a different tar-
geted rationale, and is focussed on alleviating different
outcome domains of tinnitus. For example, sound-based
interventions, such as hearing aids and sound genera-
tors, intend to reduce loudness (e.g. [8]), whilst psycho-
logically informed interventions are intended to improve
mental health and wellbeing (e.g. [9]). Therefore, any
agreed list of outcome domains is likely to be more ap-
propriate for one intervention strategy than another.
This review [6] supported an informed choice about
what are the major intervention strategies to be consid-
ered in the present study. Intervention strategies most
commonly reported from 2006 to 2015 were pharmaco-
logical (n = 66/228), electrophysiological (n = 59), sound
therapy (n = 56) and psychological (n = 47). The majority
of trials evaluating electrophysiology-based interventions
are restricted to a small number of candidates recruited
to experimental research studies, and so this interven-
tion strategy is not part of standard clinical practice.
Hence, a decision was made to focus the Delphi process
on sound-, psychology-, and pharmacology-based inter-
ventions to create three intervention-specific Core Out-
come Domain Sets.
It is vital that all key stakeholders are involved in the
development of a Core Outcome Domain Set to ensure
that it has broad relevance. Patients and members of the
public with lived experience of a condition are valued
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stakeholders in the development of relevant Core Out-
come Sets because they have first-hand experience of that
condition [10]. These groups are henceforth collectively
referred to as ‘health care users’. Instances have arisen in
previous Core Outcome Set work where health care users
have identified outcome domains as important that were
previously overlooked [11] or previously thought to be of
little importance [12] (see also [13]). One of the attractive
features of the Delphi process to health care users is the
ability to provide anonymity to all respondents which can
offset the shortcoming of conventional means of pooling
opinions obtained from a group interaction where there
can be power differentials between different stakeholder
groups [10, 14, 15]. Nevertheless, Core Outcome Set de-
velopers have somewhat limited experience in engaging
with health care users in the process of creating consensus
[10, 16], and previous studies have reported low rates of
recruitment [17]. The design of the present Delphi process
incorporates several different methods for promoting the
involvement and participation of health care users with
lived experience of tinnitus to address the secondary re-
search question concerning what methods work well for
recruiting and retaining health care users, and what
methods do not work so well.
In summary, further research work is urgently needed
to advance the standards for clinical trials of interven-
tions for tinnitus by developing an agreed list of out-
come domains, distinct elements of tinnitus, that are
critically important for determining whether a treatment
has worked, using a process that promotes input from
health care users and professionals with experience in
tinnitus. This protocol defines the COMIT’ID study
which uses a Delphi process and face-to-face meetings
to establish consensus on which outcome domains should
be measured when assessing the effect of sound-based,
psychology-based, and pharmacology-based interventions
in clinical trials for tinnitus.
Aims
The primary aims of the COMIT’ID study are to:
1. Establish three Core Outcome Domain Sets, one for
each of the main intervention strategies (sound-,
psychology-, and pharmacology-based)
2. Identify the key outcome domains that are common
across all three Delphi processes.
Two secondary aims are to:
3. Identify the strengths and limitations of the study
design with respect to methods for recruiting and
for reducing attrition of health care users
4. Investigate whether participation by professional
experts in the Delphi process affects their
subsequent use of the Core Outcome Domain Set,
compared with those who do not participate.
Methods
We will use the Delphi process to achieve a consensus
of opinion from broadly representative and international
expert stakeholder groups [15]. This is an observational
study design comprising three independent Delphi pro-
cesses, sponsored by the University of Nottingham and
managed by the National Institute for Health Research
(NIHR) Nottingham Biomedical Research Centre. A pro-
spective study protocol was registered in the Core Out-
come Measures in Effectiveness Trials (COMET) database
[18]. This protocol describes version 2.0 (dated 14 March
2017), that was approved by the Proportionate Review
Sub-committee of the West Midlands – Solihull Research
Ethics Committee (REC reference 17/WM/0095, IRAS
reference 220112) on 21 March 2017.
Research steering group
A Research Steering Group has been appointed to oversee
and manage the project. The group comprises inter-
national colleagues representing the identified interven-
tion approaches (HFH, BM, AL), a patient and public
involvement and engagement manager (AH) two health
care users with lived experience of tinnitus, referred to as
Public Research Partners (VC, BT), and the Study Man-
agement Team (KF, HS, DAH). The role of the Research
Steering Group is to:
1. Support the development of the study protocol,
specifically commenting on the feasibility of the
Delphi process, reviewing study documentation
(e.g. advertisements, Information Sheets, video
instructions for the survey, website content) and to
participate in a pilot of round 1 of the Delphi survey
2. Review the list of outcome domains and associated
descriptions, specifically commenting on the readability
of the outcome descriptions, the appropriateness of the
grouping of outcomes into categories and providing
any additional outcomes that they believe should be
included in the first round.
Eligibility criteria for the Delphi panels
A range of expertise within the panel is considered to be
an important quality criterion for development of a Core
Outcome Domain Set [19]. We will, therefore, seek to
include representatives from four key stakeholder groups
that may be particularly interested in managing chronic
subjective tinnitus in adults. Specific inclusion criteria
have been defined for each stakeholder group:
1. Health care users must have the experience of living
with tinnitus for 3 months or more and have had
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experience with at least one sound-, psychology-, or
pharmacology-based intervention for their tinnitus,
or have the intention of undergoing that treatment
in the future
2. Health care practitioners must have a clinical
qualification, be currently employed by a public or
private institution that provides a tinnitus service to
patients, have specific experience in assessing,
diagnosing or managing chronic subjective tinnitus
in adults who receive, or have received, a sound-,
psychology-, or pharmacology-based intervention.
3. Clinical researchers must have an academic
qualification, be currently employed by a research
organisation, have current or ‘recent-past’ experience in
clinical research with studies that focus on questions of
clinical efficacy (benefit) of a sound-, psychology-, or
pharmacology-based tinnitus intervention in humans
(i.e. a co-author on a relevant peer-reviewed journal
publication in the past 3 years)
4. Commercial representatives must be currently
employed by a company that develops, manufactures
or sells relevant sound-, or pharmacology-based
product(s) that may be used for alleviating tinnitus.
Funders must be currently contracted by an
organisation that has funded tinnitus research
projects addressing sound-, psychology-, or
pharmacology-based interventions in the last
3 years
General eligibility for participation in the Delphi
process includes men and women aged 18 years or older,
with sufficient command of English to read, understand
and independently complete the questionnaires. An
online screening stage will ask all participants to self-
certify that they are an ‘expert’ in at least one of the
three tinnitus-intervention strategies.
All enrolled Delphi panellists will be eligible to register
their interest in attending a 1-day consensus meeting.
However, allocation of places will be limited to those re-
spondents who complete all three rounds of the online
survey. None of the Research Steering Group members
will be allowed to vote on domains in the consensus
meetings because this risks inadvertently introducing a
power differential across participants, but they can enrol
in the online Delphi surveys (with the exception of KF
and HS who will have access to the dataset for all ana-
lyses). Each expert panellist is permitted to enrol for
more than one Delphi process if they meet the eligibility
criteria, but would be invited to attend only one consen-
sus meeting.
Panel size and justification
There is no agreed method to statistically calculate a
sample size for online Delphi surveys or for consensus
meetings and no criteria against which a sample size
choice can be judged (e.g. [20, 21]). Some individual
studies indicate that stakeholder groups of around 20
can provide stable results [21]; and this defines our
minimum sample size. However, one of the key deciding
factors is that panel membership should adequately
represent their corresponding stakeholder group (health
care users, clinical researchers, etc.). Another key deciding
factor is pragmatic; the global pool of experts meeting our
eligibility criteria differs from one intervention to another.
So it is not feasible for all three online Delphi surveys
to have the equivalent sample size or target number of
stakeholders.
Across the three Delphi processes, we aim to recruit a
minimum target of 260 and an upper target of 420 ex-
perts spanning the range of stakeholder roles. Sound-
based tinnitus interventions are the most accessible
intervention in the UK [6] and devices and smartphone
apps are widely available for self-management. Thus, a
large pool of stakeholders is expected. Therefore, the
intention is to enrol into the sound-based Delphi survey
60–90 health care users, 20–30 health care practitioners,
20–30 clinical researchers, and 20–30 commercial repre-
sentatives and/or funders. For psychology-based tinnitus
interventions, there are no specific commercial avenues
or funding streams. Therefore, for this Delphi survey, we
will enrol 40–60 health care users, 20–30 health care
practitioners, and 20–30 clinical researchers. Pharmaco-
logical interventions are not widely accessible because
there are no licensed drugs for tinnitus [22]. Instead,
there are some established medications for comorbid
symptoms such as insomnia, depression, and anxiety.
Therefore, the number of professionals and members
of the public with knowledge and experience of these
interventions is expected to be more limited. For the
pharmacology-based survey, the intention is to enrol
30–60 health care users, 10–20 health care practitioners,
10–20 clinical researchers, and 10–20 commercial repre-
sentatives and/or funders. Experts will be allocated to the
appropriate online survey based on their self-declared
expertise.
The consensus meetings require in-depth discussions
with smaller groups. Up to 20 expert panellists will be
invited to participate in each of three face-to-face group
consensus meetings (corresponding to the sound-,
psychology-, or pharmacology-based online Delphi sur-
veys). Enrolment will be balanced across stakeholder
groups, where possible.
Recruitment methods
Taking a business-informed approach has been shown to
be beneficial to recruitment in several multicentre clin-
ical trials [23]. Adopting an explicit marketing plan, en-
gaging charities or participants to act as champions,
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delivering effective messages to multiple audiences at
multiple levels and achieving clinician and public buy-in
are all known effective ‘business’ comp-style components
[24]. We are using a purposive sampling approach to
recruit health care users from both clinical and non-
clinical settings, and to recruit professional experts
who maximise the international relevance of the study
findings (see [13]). We have created a study recruitment
plan with adequate resource allocation at the outset. Re-
cruitment strategies include a number of planned methods
approved by the Research Ethics Committee, some of
which will be general and others will be targeted at par-
ticular stakeholder audiences. General e-promotion routes
include a study webpage (http://www.hearing.nihr.ac.uk/
research/outcome-measures-for-clinical-trials), a ‘research
news’ feature on the health care user community website
(https://www.tinnitustalk.com/), and regular updates on
study progress via social media channels such as
Twitter (e.g. @COMITIDStudy) and Facebook (e.g.
hearingnihr).
Health care users will be targeted using several differ-
ent planned recruitment routes. UK ‘Tinnitus Awareness
Week’ (6–12 February 2017) shortly preceded the study
launch and provided a platform to inform patients about
this study and the importance of accurately measuring
tinnitus complaints. An introductory feature published
in the British Tinnitus Association Quiet magazine
highlighted the upcoming study and enabled people to
register for the study [25]. In addition, health care users
in the UK are to be targeted using a traditional NHS re-
cruitment route with five audiology centres designated
as Participant Identification Centres, in addition to the
lead site in Nottingham. Sites will display study posters
in the audiology clinic waiting room, and hand out
Participant Information Sheets, as appropriate. A small
number of health care professionals in Europe will do the
same in their tinnitus clinics, dependent on gaining appro-
priate local regulatory approval. Specific e-promotion
routes include several patient organisations that have
agreed to support the project by publishing newsletter
articles and announcements to their members (e.g. the
British Tinnitus Association, Action on Hearing Loss,
the Deutsche Tinnitus-Liga e.V., the German Tinnitus
Foundation Charité, and Association France Acouphènes).
And finally, the lead study site has a participant database
containing email contacts for approximately 1000 health
care users who have self-declared tinnitus.
To recruit health care professionals, a number of pro-
fessional networks and organisations will also circulate
invitations to their membership (British Society of Audi-
ology, British Academy of Audiology, ENT and Audiology
News, the TINNET network funded by an EU COST Ac-
tion BM1306, the International Collegium of Rehabilita-
tive Audiology, and the Pharmacological Interventions for
Hearing Loss Working Group at the Hearing Centre of
Excellence in the USA). Collectively, these networks reach
out to tens of thousands of professionals across the globe,
but the disadvantage is that the approach can be some-
what impersonal. Parallel routes for recruiting health care
professionals will, therefore, involve personal invitation via
email or face-to-face contact. The Study Management
Team has created a list of potential participants with rele-
vant expertise using manual searches of the following in-
formation sources: first and last authors of relevant
conference proceedings in last 3 years (e.g. Tinnitus Re-
search Initiative, International Tinnitus Seminar, British
Tinnitus Association conference); corresponding authors
for each clinical trial of tinnitus identified in our previous
systematic review [6]; and all authors of systematic reviews
of tinnitus (Cochrane or otherwise) published in the
preceding 5 years. An email request for relevant staff
nominations has also been sent to members of the
Hearing Industry Research Consortium representing the
hearing-aid sector.
We will also personally approach editors of scholarly
journals in the fields of audiology and otology. They will
not be considered as a separate stakeholder because
this role tends to be secondary to one of the above pro-
fessional occupations. But participants who are journal
editors will be recorded, allowing for this subgroup of
data to be examined for any notable response differ-
ences during the analysis phase.
The Delphi survey
Three (parallel, independent) international Delphi sur-
veys will be managed online using DelphiManager soft-
ware maintained by the Core Outcome Measures in
Effectiveness Trials (COMET) initiative (University of
Liverpool: http://www.comet-initiative.org/). Each pan-
ellist will receive a Unique Identification Code and an
e-link to the webpage for whichever survey matches
their self-nominated expertise. Confirmation of eligible
expertise will be collected online. A video explanation
will illustrate how to complete the online tool. A flow-
chart of the study is shown in Fig. 1.
We will use a modified Delphi technique whereby we
identify a ‘long-list’ of candidate outcomes prior to the
first survey round, through systematic procedures that
involve professional and public stakeholders and pool
several independent sources of information [13, 26, 27].
For each outcome, we will provide the same plain-
language description to participants in each stakeholder
group. Each survey will comprise the same three sequen-
tial rounds, but will always be completed from the per-
spective of one of the interventions. All outcome domains
will be retained from one round to the next presented in
the same fixed order.
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The pre-Delphi stage involving health care users as Public
Research Partners
We have completed the pre-Delphi stage and this cre-
ated a finalised set of 66 outcome domains, each with a
short plain-language description, grouped into 13 do-
main categories; the main content of the online Delphi
surveys. Patient involvement has been an integral and
transformative step of the study design process. To im-
prove the appeal to health care users and to reduce at-
trition, two Public Research Partners on the Research
Steering Group and one independent member of the
public commented on the feasibility of the Delphi sur-
vey design, and reviewed study documentation (adver-
tisements, Information Sheets, video instructions for
the survey). In line with recommended considerations
[10; 13], we also used qualitative research data gathered
from health care users to make informed decisions
about the main content of the online Delphi surveys and
to ensure that outcome domain concepts are explained in
ways that patient participants can understand and gener-
ate meanings which are consistent across all Delphi stake-
holder groups. This goal is also highly relevant for any
participants whose native language is not English; a factor
for consideration in our international Delphi process.
The COMIT’ID Study Management Team scoped out
information from three different sources. The first in-
formation source was a systematic review of outcome
domains used in clinical trials of tinnitus treatments in
adults which identified 62 outcome domains [6]. The
second information source was an ongoing study that
identified 64 outcome domains through thematic ana-
lysis of the items taken from 23 commonly reported
tinnitus questionnaires [Fackrell, personal communication].
Both of these sources largely reflect outcomes that re-
searchers have thought important to measure. The third
source was a systematic review of dimensions of tinnitus-
related complaints reported by patients and their significant
others using questionnaire- and interview-based methods
[28]. This source identified 43 outcome domains that
reflected outcomes which patients considered important to
them. This scoping process identified a total of 124 distinct
outcome domains, after duplicates had been consolidated
(see Fig. 2). For each outcome domain, associated examples
were taken from each data source to aid interpretation of
meaning for each outcome domain.
Our Research Steering Group, in particular our two
Public Research Partners, informed our decision to reduce
the long-list of outcome domains in order to improve the
likelihood of completing all items in the Delphi survey.
Discussion of each outcome domain and examples re-
duced the list of 124 by 57. Fifteen outcome domains were
comorbidities that were associated with, but not specific
to, tinnitus and so these can be considered out of the
scope of this Core Outcome Domain Set and consequently
were removed. Comorbidities were primarily related to
hearing and mental health difficulties with examples in-
cluding ‘hearing handicap’, ‘speech perception’, ‘reduced
sound tolerance’, and ‘depression’.
Our Public Research Partners strongly argued that 13
outcome domains were broad concepts that were already
encapsulated by other outcome domains in the list. Such
hierarchies of constructs were considered a risk by con-
fusing participants when rating the importance of indi-
vidual outcome domains in the online Delphi survey.
For example, ‘cognitive difficulties’ was already captured
Fig. 1 A schematic diagram of the Delphi process, including a time
schedule of enrolment, online rounds 1–3, and the face-to-face
consensus meetings. Only the initial question varies between the
three surveys, as shown. The coloured histograms represent the
planned graphical format of the results from the previous round. The
single (yellow) histogram represents results for the peer stakeholder
group. The Purple, green, and red histograms represent results for each
relevant stakeholder group (peer and otherwise)
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by ‘concentration’, ‘confusion’, ‘ability to ignore’ and ‘tin-
nitus-related thoughts’ and ‘health-related quality of life’
was already covered by ‘impact on relationships’, ‘impact
on individual activities’, ‘impact on social life’, ‘impact on
work’, and ‘sexual difficulties’. The Public Research Part-
ners recommended that such broad concepts should be
removed from the long-list and instead used as the cat-
egory label.
Eight domains were not considered to be suitable as
tinnitus-specific outcomes; two because they were re-
stricted to the clinician’s diagnostic assessment and six
because they were highly specific to the fidelity of the
intervention. Diagnostic items were ‘causes of tinnitus’
and ‘tinnitus duration’. Intervention items were ‘adequacy
of blinding’, ‘credibility of sham intervention (control)’,
‘credibility of real intervention’, ‘needling sensation
(acupuncture)’, ‘masking (sound therapy)’, and ‘thera-
peutic alliance’. It is interesting to note that all of these
candidates originated from the two information sources
which reflected what researchers have thought import-
ant to measure, mostly from the systematic review of
clinical trials [6].
A number of outcome domains were judged to relate
to specific ways in which an outcome domain could be
measured and thus, on a conceptual/semantic level at
least, to be broadly equivalent to one another. For ex-
ample, an ‘active task to distract or cope with tinnitus’
and ‘purposefully protecting or reducing the chance of
potential problems’ were both considered different ways
to measure the same health construct ‘coping’. This
Fig. 2 Flow diagram illustrating the pre-Delphi stage that has been completed with the involvement of health care users as Public
Research Partners
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recommendation resulted in ten outcome domains being
consolidated in the final version of the long-list under
existing outcome domains ‘tinnitus loudness’, ‘tinnitus
quality’, ‘coping’, and the category ‘body structures and
functions’. Three further outcome domains were consol-
idated with the existing outcome domain ‘fear’ because
they were considered by the Public Research Partners to
be overlapping examples of the same concept (i.e. ‘fear
for health’, ‘fear for quality of life’, and ‘fear of tinnitus be-
coming worse’).
Finally, eight outcome domains were consolidated be-
cause they were specific examples of what could be con-
sidered as a form of adverse reaction (i.e. ‘drug safety
and tolerability’, ‘safety’, ‘safety and tolerability’, ‘side effects’,
‘tolerability’, ‘headache’, ‘pain frequency’, and ‘pain inten-
sity’). ‘Adverse reaction’ was, therefore, created as a new
outcome domain term.
These health care user-led decisions established a re-
vised long-list of 68 distinct outcome domains. The Re-
search Steering Group next took careful steps to identify
the appropriate language for use in the Delphi survey.
The task of phrasing each outcome domain, writing
plain language concept definitions, and phrasing the
names for domain category groupings was an iterative
procedure conducted over two half-day workshop ses-
sions with members of the Study Management Team
working closely with the two Public Research Partners.
Resulting outcome domain terms, concept definitions
and category labels were reviewed by 14 members of the
British Tinnitus Association’s Users’ panel and five clin-
ical experts who were members of the British Tinnitus
Association Professional Advisory Committee, and all
members of the Research Steering Group for face valid-
ity, understanding, and acceptability.
At this stage, two further revisions were made to the
long-list, arising from both health care user-led and
professional-led recommendations about semantic
equivalence. The first was that the outcome domain
‘bothered’, defined as ‘being disturbed by tinnitus or
finding it a nuisance’, was consolidated with ‘annoyance’.
The second was that the outcome domain ‘frustration’, de-
fined as ‘feeling unable to change or achieve something
because of or in relation to tinnitus’, was felt to be already
represented by ‘annoyance’ and ‘upset’ and, therefore, was
consolidated with these. Additional file 1 reports the fina-
lised set of 13 domain categories, 66 outcome domains,
and short plain language descriptions. Categories and out-
come domains will be presented within the Delphi surveys
in alphabetical order to avoid potential weighting [26].
Round 1
For each outcome domain, participants will be asked to
think about the importance of each tinnitus outcome
domain and indicate how important it is to measure
when deciding if a sound-based/psychology-based/
pharmacology-based tinnitus treatment is working. Par-
ticipants will be asked to score each outcome domain
using the GRADE scale of 1–9, where 1 represents least
important and 9 represents most important [29]. Select-
ing response options 1–3 indicates that the domain is
‘not important’, whilst 7–9 indicates that the domain is
‘critically important’ in deciding whether a tinnitus
treatment is effective. Scores 4, 5, and 6 indicate that
the outcome domain is ‘important but not critical’. If a
participant feels that they did not understand a particu-
lar outcome, they will be able to select ‘unable to score’.
Following each outcome and at the end of the round,
optional open-text boxes will enable participants to add
any comments. In round 1, participants will be able to
propose additional outcome domains. These additional
outcome domains will be reviewed and coded by two
Study Management Team members, with appropriate
plain-language concept definitions, to ensure that they
represent new items for inclusion in rounds 2 and 3.
Where uncertainty exists the Research Steering Group
will be consulted, and all new outcome domain terms,
concept definitions and category labels will be reviewed.
Rounds 2 and 3
Participants will be eligible to continue to rounds 2 and
3 if they have responded to at least 40% of the outcome
domains in the previous round. Corresponding data
from those participants who responded to less than 40%
will be removed. In rounds 2 and 3, all participants will
receive the same list of outcomes with feedback tailored
according to their Delphi allocation. The purpose of
round 2 will be to enable participants to reflect on their
scores in light of the viewpoint of their stakeholder
peers, and to score the outcomes again. The purpose of
round 3 will be to enable participants to reflect on their
scores in light of the viewpoint of their stakeholder peers
and all other stakeholder groups, and to score the out-
comes again. Results will be presented graphically as
well as numerically to improve visual appeal (Fig. 2).
After round 3, a short questionnaire with open- and
closed-text response options will be emailed to all par-
ticipants to collect feedback on their experience of being
a participant, in addition to their perceptions of our
strategies for recruiting and for reducing attrition of pro-
fessional and health care users’ stakeholders.
Consensus meeting
Professionals and health care users who have completed
all three rounds of the Delphi survey and responded to
at least 90% of the outcome domains in round 3 will be
eligible to participate in the consensus meeting. As far
as possible, allocated places will maintain the balance
across stakeholder groups (e.g. 50% health care users/
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50% professionals) and will include non-UK, non-native,
English language speakers. The purpose will be to agree
a final Core Outcome Domain Set for each intervention
category. Separate discussion within each meeting will
include anonymised voting on each outcome as either
‘In’ or ‘Out’ (e.g. using electronic keypads which will create
histograms and descriptive statistics ‘live’, to be displayed
in the meeting).
Consensus criteria
Consensus recommendations for each intervention cat-
egory will be guided by the respective round-3 results.
We will include domains for which 70% or more of the
participants in each stakeholder groups score 7–9, and
fewer than 15% score 1–3 [30]. We will exclude domains
for which 70% or more of the participants in each stake-
holder groups score 1–3, and fewer than 15% score 7–9
[30]. These decisions will be taken without further dis-
cussion because time at the consensus meeting will be
limited. At the consensus meeting, the moderated dis-
cussion, voting and decisions will be guided as follows:
 For outcomes recommended to be included based
on the round-3 analysis (70% scored 7–9), domains
will be included if at least 70% of participants vote ‘In’
 For outcomes where at least 50% of more than one
stakeholder group scored 7–9 on the round-3
analysis, domains will be included if at least 70% of
participants vote ‘In’
 For outcomes where less than 50% of the participants
in all stakeholder groups or at least 50% of only one
stakeholder group scored 7–9 on the round-3 analysis,
domains will be included only if at least 70% of
participants vote ‘In’
If consensus is not reached after two rounds of voting,
a ‘majority rules’ approach will be applied.
In the very final step, the Study Management Team
will seek to establish a common cross-cutting Core Out-
come Domain Set by identifying those outcome domains
that were voted for inclusion in all three intervention-
specific Core Outcome Domain Sets.
Observational cohort study
We aspire to conduct a prospective observational cohort
study to determine if participation of clinical researchers
in the Delphi process increases uptake of the recom-
mended Core Outcome Domain Sets for trials of sound-
, psychology-, and pharmacology-based interventions for
chronic subjective tinnitus in adults, compared with re-
searchers who did not participate. This investigation will
be conducted on the basis of the implementation of the
recommendations in published reports of clinical trials
in the 7 years after the Core Outcome Domain Sets are
published.
Analyses
The data from each Delphi round will be subjected to
descriptive statistics, such as number completing each
round, gender, country, region, native English language
speaker (or not), and retention rate at rounds 2 and 3.
We will plot the distribution of rating scores within each
stakeholder group (including the ‘unable to score’ option
and any missing data), and we will investigate attrition
bias by comparing these plots across participants who
complete successive rounds versus those who withdraw
at rounds 2 or 3 [31]. We will also compare the distribu-
tion of rating scores for native and non-native English
language speakers. Withdrawal and language are both
factors that may affect how representative the final
consensus might be of the target population. A separate
analysis will assess the shifts in scores across rounds as
a consequence of considering the anonymised feedback
from other participants. The distribution of the scores
for each outcome domain will be calculated for each
stakeholder group within each intervention-specific
Delphi survey.
The data from the feedback questionnaire will comprise
open-text responses and these will be analysed using a
thematic analysis approach to address one of the second-
ary objectives. Uptake of the recommendations will be
analysed by calculating the number and proportion of
authors who have implemented and referenced the
COMIT’ID study recommendations in trials reported
up to 7 years after their publication, comparing data be-
tween groups using non-parametric statistics (p < 0.05).
Dissemination
Any important changes to eligibility criteria that are ap-
proved as a protocol modification will be communicated
to our list of potential participants and advertised via all
general e-promotion routes. Data from the final analyses
of the Delphi surveys, consensus meetings and feedback
questionnaire will be presented at relevant national and
international conferences, including the British Tinnitus
Association, the British Society of Audiology, the Tin-
nitus Research Initiative and the International Tinnitus
Seminar. Several peer-reviewed publications are also
planned; one addressing all primary objectives and one
addressing the secondary objective for recruiting and for
reducing attrition of health care users. Our findings will
be further disseminated to members of the public and
clinicians through specialist magazine articles, and our
patient organisation supporters. Participants will not be
identified in any publications.
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Discussion
This paper describes the design of a Delphi process to
develop a Core Outcome Domain Set for sound-,
psychology-, and pharmacology-based interventions for
chronic subjective tinnitus in adults, to identify the
strengths and limitations of the study design with re-
spect to methods for recruiting and for reducing attri-
tion of health care users across English-speaking and
non-English-speaking countries, and to determine if
participation increases adoption of the recommendations
in the long term. We are not proposing that outcomes in
a particular trial should be restricted to only those in the
agreed list, but instead we expect that the Core Outcome
Domains will be collected and reported in future trials,
alongside additional outcomes that are deemed relevant.
Results from the feedback survey can be used to inform
the design of future consensus projects that seek to recruit
and retain health care users.
To our knowledge, it is the first time that the Delphi
technique incorporating these methods has been used
for developing a Core Outcome Domain Set in tinnitus.
It will supersede an earlier recommendation based on an
informal 1-day workshop with 29 professional key opin-
ion leaders [32]. Other important features of this study
are that it will provide guidance for involving health care
users in the development of the design and materials for
the Delphi process. In addition to developing the Core
Outcome Domain Set, this study may also shed light on
controversial aspects within tinnitus trials, in particular
differences in opinion across the three different inter-
vention strategies concerning what is critically important
for deciding whether or not the intervention has worked.
The next steps in the process have been set out the
COMiT roadmap [33]. These include a systematic ap-
praisal of candidate instruments that adequately map
onto the Core Outcome Domain Set and a statement
about the preliminary Core Outcome Sets for sound-,
psychology, and pharmacology-based interventions, with
recommendations for further psychometric evaluation if
required.
Trial status
At the time of manuscript submission, all three Delphi
surveys were open to recruitment.
Additional file
Additional file 1: Table of domain categories, tinnitus-related outcome
domains and concept definitions for all 66 outcome domains co-produced
with health care users at the pre-Delphi stage. (XLSX 16 kb)
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